USANA Health Sciences (NYSE:USNA) Upgraded to Hold by Zacks Investment Research

USANA Health Sciences (NYSE:USNAGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Zacks.com reports.

According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system. “

Several other brokerages also recently commented on USNA. TheStreet downgraded shares of USANA Health Sciences from a “b” rating to a “c+” rating in a research note on Wednesday, February 9th. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Finally, DA Davidson decreased their target price on shares of USANA Health Sciences from $86.00 to $76.00 in a research note on Wednesday, April 27th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, USANA Health Sciences presently has an average rating of “Buy” and a consensus price target of $105.00.

USNA stock opened at $71.62 on Friday. The company has a market capitalization of $1.37 billion, a PE ratio of 13.24 and a beta of 0.84. USANA Health Sciences has a one year low of $69.82 and a one year high of $107.85. The company’s 50 day moving average price is $79.25 and its two-hundred day moving average price is $91.16.

USANA Health Sciences (NYSE:USNAGet Rating) last issued its earnings results on Tuesday, April 26th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. USANA Health Sciences had a net margin of 9.41% and a return on equity of 27.04%. During the same period in the prior year, the business earned $1.45 EPS. As a group, equities analysts forecast that USANA Health Sciences will post 5.28 EPS for the current fiscal year.

In other news, COO Walter Noot sold 1,153 shares of the business’s stock in a transaction on Monday, February 14th. The shares were sold at an average price of $92.02, for a total transaction of $106,099.06. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gilbert A. Fuller sold 312 shares of the business’s stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $89.62, for a total transaction of $27,961.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,653 shares of company stock worth $600,825. 0.36% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Crew Capital Management Ltd. bought a new position in USANA Health Sciences in the 4th quarter worth about $202,000. UBS Asset Management Americas Inc. boosted its stake in USANA Health Sciences by 29.4% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 13,284 shares of the company’s stock worth $1,225,000 after purchasing an additional 3,017 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in USANA Health Sciences by 83.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 5,664 shares of the company’s stock worth $522,000 after purchasing an additional 2,569 shares in the last quarter. Blue Bell Private Wealth Management LLC bought a new position in USANA Health Sciences in the 4th quarter worth about $101,000. Finally, Martingale Asset Management L P boosted its stake in USANA Health Sciences by 141.0% in the 3rd quarter. Martingale Asset Management L P now owns 12,785 shares of the company’s stock worth $1,179,000 after purchasing an additional 7,480 shares in the last quarter. Hedge funds and other institutional investors own 55.72% of the company’s stock.

About USANA Health Sciences (Get Rating)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.

See Also

Get a free copy of the Zacks research report on USANA Health Sciences (USNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.